Anti-IKZF1 monoclonal antibody
Pre-made anti-IKZF1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to IKZF1/IKZF1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1008-Ab-1/ GM-Tg-hg-IP1008-Ab-2 | Anti-Human IKZF1 monoclonal antibody | Human |
GM-Tg-rg-IP1008-Ab-1/ GM-Tg-rg-IP1008-Ab-2 | Anti-Rat IKZF1 monoclonal antibody | Rat |
GM-Tg-mg-IP1008-Ab-1/ GM-Tg-mg-IP1008-Ab-2 | Anti-Mouse IKZF1 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1008-Ab-1/ GM-Tg-cynog-IP1008-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IKZF1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1008-Ab-1/ GM-Tg-felg-IP1008-Ab-2 | Anti-Feline IKZF1 monoclonal antibody | Feline |
GM-Tg-cang-IP1008-Ab-1/ GM-Tg-cang-IP1008-Ab-2 | Anti-Canine IKZF1 monoclonal antibody | Canine |
GM-Tg-bovg-IP1008-Ab-1/ GM-Tg-bovg-IP1008-Ab-2 | Anti-Bovine IKZF1 monoclonal antibody | Bovine |
GM-Tg-equg-IP1008-Ab-1/ GM-Tg-equg-IP1008-Ab-2 | Anti-Equine IKZF1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1008-Ab-1/ GM-Tg-hg-IP1008-Ab-2; GM-Tg-rg-IP1008-Ab-1/ GM-Tg-rg-IP1008-Ab-2; GM-Tg-mg-IP1008-Ab-1/ GM-Tg-mg-IP1008-Ab-2; GM-Tg-cynog-IP1008-Ab-1/ GM-Tg-cynog-IP1008-Ab-2; GM-Tg-felg-IP1008-Ab-1/ GM-Tg-felg-IP1008-Ab-2; GM-Tg-cang-IP1008-Ab-1/ GM-Tg-cang-IP1008-Ab-2; GM-Tg-bovg-IP1008-Ab-1/ GM-Tg-bovg-IP1008-Ab-2; GM-Tg-equg-IP1008-Ab-1/ GM-Tg-equg-IP1008-Ab-2 |
Products Name | Anti-IKZF1 monoclonal antibody |
Format | mab |
Target Name | IKZF1 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-IKZF1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1008-Ag-1 | Recombinant multi-species IKZF1/ CVID13/ Hs.54452 protein |
ORF Viral Vector | pGMAP000221 | Human IKZF1 Adenovirus plasmid |
ORF Viral Vector | vGMAP000221 | Human IKZF1 Adenovirus particle |
ORF Viral Vector | pGMLPm001762 | mouse Ikzf1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm001762 | mouse Ikzf1 Lentivirus particle |
Target information
Target ID | GM-IP1008 |
Target Name | IKZF1 |
Gene ID | 10320,22778,305501,693936,483231,101085701,541154,100052437 |
Gene Symbol and Synonyms | 5832432G11Rik,CVID13,hlk-1,Hs.54452,IK1,IKAROS,IKZF1,LyF-1,LYF1,mKIAA4227,PPP1R92,PRO0758,RGD1562979,Zfpn1a1,ZNFN1A1 |
Uniprot Accession | Q13422 |
Uniprot Entry Name | IKZF1_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | Cancer |
Gene Ensembl | ENSG00000185811 |
Target Classification | Tumor-associated antigen (TAA) |
The target: IKZF1, gene name: IKZF1, also named as CVID13, Hs.54452, IK1, IKAROS, LYF1, LyF-1, PPP1R92, PRO0758, ZNFN1A1. This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to the fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. Most isoforms share a common C-terminal domain, which contains two zinc finger motifs that are required for hetero- or homo-dimerization, and for interactions with other proteins. The isoforms, however, differ in the number of N-terminal zinc finger motifs that bind DNA and in nuclear localization signal presence, resulting in members with and without DNA-binding properties. Only a few isoforms contain the requisite three or more N-terminal zinc motifs that confer high affinity binding to a specific core DNA sequence element in the promoters of target genes. The non-DNA-binding isoforms are largely found in the cytoplasm, and are thought to function as dominant-negative factors. Overexpression of some dominant-negative isoforms have been associated with B-cell malignancies, such as acute lymphoblastic leukemia (ALL). [provided by RefSeq, May 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.